Related Experiment Videos
[Long-term therapy of hypertrophic obstructive and non-obstructive cardiomyopathy with nifedipine in comparison to
Insights
Nifedipine improved diastolic heart function in hypertrophic cardiomyopathy patients, while Propranolol better addressed subjective symptoms. Nifedipine is a viable option when other medications are contraindicated or ineffective.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertrophic cardiomyopathy (HCM) presents with obstructive or non-obstructive patterns.
- Current treatments for HCM include beta-blockers and calcium channel blockers like Verapamil.
- Evaluating alternative or adjunctive therapies for HCM is crucial.
Purpose of the Study:
- To investigate the effects of Nifedipine on subjective and objective parameters in patients with hypertrophic cardiomyopathy.
- To compare the efficacy of Nifedipine with Propranolol in managing HCM symptoms and cardiac function.
- To determine the potential role of Nifedipine in HCM management, particularly in specific patient subgroups.
Main Methods:
- A 6-month study involving 24 patients diagnosed with hypertrophic obstructive cardiomyopathy (HOCM) and hypertrophic non-obstructive cardiomyopathy (HNOCM).
- Patients received a daily dose of 30 mg Nifedipine.
- Subjective symptoms and objective parameters, including systolic and diastolic heart function (assessed via systolic time intervals and cardiographic criteria of the apex), were evaluated and compared to Propranolol.
Main Results:
- Propranolol demonstrated a greater improvement in subjective symptoms compared to Nifedipine.
- Nifedipine did not significantly influence systolic heart function, unlike Propranolol.
- Nifedipine improved diastolic heart function to a similar extent as Propranolol.
Conclusions:
- Nifedipine may be a reasonable therapeutic option for HCM patients with contraindications to beta-receptor blockers or Verapamil, or those unresponsive to these medications.
- Combination therapy with beta-blockers could be considered if Nifedipine alone does not yield satisfactory results.
- Further research into Nifedipine's role in diastolic dysfunction in HCM is warranted.
Abstract:
On 24 patients with ascertained hypertrophic obstructive cardiomyopathy and hypertrophic non-obstructive cardiomyopathy in a long-term experiment over 6 months the effect of 30 mg Nifedipin per day on subjective and objective parameters was investigated and compared with Propranolol. The subjective symptoms were in a larger extent improved by Propranolol than by Nifedipin. In contrast to Propranolol Nifedipin had no influence on the systolic function on the basis of the systolic time intervals. The diastolic heart function, assessed by means of the cardiographic criteria of the apex, was improved by Nifedipin in circa the same extent as by Propranolol. The results altogether allow the conclusion that the application of Nifedipin seems to be reasonable in patients with contraindication to beta-receptor-blockers or Verapamil or when there is no reaction to these preparations. When there is no satisfying result, a combination with beta-blockers should also be attempted.